CENTOCOR, INC.
🇺🇸United States
A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis
Phase 3
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: Placebo - Controlled Period (CP)Drug: Ustekinumab 45 mg - CPDrug: Placebo to ustekinumab 45 mg - after CPDrug: Ustekinumab 45 mg - after CP
- First Posted Date
- 2008-09-05
- Last Posted Date
- 2013-03-29
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT00747344
A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Phase 2
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 187
- Registration Number
- NCT00718718
A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma
Phase 2
Withdrawn
- Conditions
- Asthma
- Interventions
- Biological: CNTO 148 / GolimumabBiological: placebo
- First Posted Date
- 2008-05-12
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Centocor, Inc.
- Registration Number
- NCT00675649
A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector
Early Phase 1
Completed
- Conditions
- PsoriasisRheumatoid ArthritisPsoriatic ArthritisAnkylosing Spondylitis
- Interventions
- Device: Pre-filled Auto-injector Containing Placebo
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT00643526
An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer
Phase 2
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT00537381
First Study of the Safety of CNTO 888 in Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Cancer
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2010-10-22
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT00537368
A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa
Phase 1
Terminated
- Conditions
- Retinitis Pigmentosa
- Interventions
- Drug: CNTO 2476
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT00458575
An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis
Phase 3
Completed
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2012-11-21
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 903
- Registration Number
- NCT00454584
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
Phase 1
Completed
- Conditions
- Lymphoma, Non-HodgkinMultiple MyelomaGiant Lymph Node Hyperplasia
- Interventions
- Drug: CNTO 328
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2014-07-01
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT00412321
An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT00402181
© Copyright 2025. All Rights Reserved by MedPath